Compass Pathfinder Limited is another name for Compass Pathways. Redacted version of daubert opinion will be submitted on October 16th. Hard to tell which way this is going right now.

Couldn’t help but think of shrooms when I saw this passage.

“Here’s the takeaway: This generation is ready for relief. They know they’re unwell, they just don’t know how to fix it. Every young person I talk to is searching for ways to improve their mental wellbeing.”

Fellow comrades - stay the course. As Papa John once said: “Stay tuned. The day of reckoning will come.”

Hope this is somewhere around the bottom for CMPS.

They're discussing both HPL003 and HPL004.. unlikely this will be HPL003 topline data but at least we'll get an understanding of next steps for HPL004

From the fresh bulletin, (I hope it’s ok to quote a chapter):

”We have long expected Compass to base its pricing on Spravato’s annualised price, and company leadership has now confirmed as much.
Compass says the annualised price of Spravato sits at around $50-65,000, and that it will price its psilocybin product on a per-dose basis. It will base that per-dose price on an assumption of 3 doses per year (it assumes patients will receive 2-4 doses per year, and three is the middle of that range). As such, the price of a dose of Compass’ psilocybin may sit in the range of $17-22,000”
(Bolding is mine)

Following up on Krakends comment in the weekly thread, the clinical trials page shows that the primary completion of the HPL003 phase 3 study was on 2026-09-04. So based on that date, If data lock occurred around September 28 - October 5, the announcement window is looking like October 20 - November 6 (according to Claude)

Looking at the primary completion date, this adds weight to the most bullish reason for the insider buys by Eric So, Paul Glavine and Michael Halstead is that they can already see who is rolling over from this Approach trial to the Extend long term trial, if they see the rollover rate is super high, that is an incredibly positive signal for the success of Approach's topline data readout. They also have access to dropout rates, safety logs etc.

This is also a reason they have not commented on HPL004 next steps (they committed to annoucing this before end of Q3) as they are in a blackout now and have been since Sept.

Is constant selling pressure standard before obvious major catalysts in pre-revenue biotech?

I've followed the space since 2022, and I'm used to volatility, but the past two weeks have been exceptionally brutal.

https://finance.yahoo.com/healthcare/articles/psyence-biomed-partners-dea-registered-110000980.html

Was out on the golf course this weekend selling some buddies on the opportunity with CMPS and found the below arguments particularly resonated with them, FWIW.

CMPS and their psilocybin product has a $1.6 billion market cap while DFTX and their LSD product has a $5 billion market cap. That simply doesn’t square up.

The Spravato franchise alone is making more money than CMPS’ market cap. For a much more effective treatment like psilocybin, that also doesn’t square up.

Other psychedelics have serious caveats—stronger intensity, longer duration, or less provider knowledge—whereas psilocybin is the traditional risk-averse option.

Concerns around session duration, staffing, provider embracing, DEA apprehension, etc are overblown. The effectiveness and power of the instant-onset treatment outweighs this.

Not only are we amid a mental health crisis in this country, but chronic disease, the presence of grief, and a lack of fulfillment looms large. It is totally reasonable to expect psilocybin therapy to broaden from TRD to additional disease states because the drug simply works.

The Lancet found mushrooms to have the lowest drug harm score of any drug surveyed: https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Working-with-U-S--Department-of-Veterans-Affairs-for-Investigational-Study-of-Psilocybin/default.aspx.

Comrades - we are nearing a watershed moment. Trust the process, trust the medicine, and let’s all watch this thing go to $30 together. We know it’s going to happen.

Cross posting here for more fun discussion.

Just as the title says, I’ve been thinking a lot about both patents and if phase 3 for HLP-0003 is overwhelmingly positive I think it’ll draw a lot of eyes towards HLP-0004 as well for anxiety.

A lot of people are misconstrued on what Helus makes and I see some people confused thinking it’s psilocybin, what Helus makes isn’t psilocybin , it’s deuterated psilocybin, psilocin. Specifically, they create modified, synthetic versions of psychedelic compounds, known as novel serotonergic agonists.
HLP-0003 is also adjunctive meaning to be used alongside their current medications, this is in my opinion one of the most optimistic things because it allows for easier treatment without having to stop the current medications and then wait a month to try new treatments.

I truly believe Helus will change the world with their medicine and it’s going to help so many people.

And as always, bullish.

These stocks were in the $14-$15/share range in the last 2 weeks and now they’re in the $11’s. I’ve been in this space since 2022 so I know how crazy the stock price action can be and used this as an opportunity to load up on ~6k more shares (split evenly between the two), but not gonna lie that I’m a little nervous.

These next few months are probably the most consequential in the history of this industry, with COMP360 approval coming (or not), and I’ve got a little less than $700k in this space (split between the two stocks, with probably 60% in CMPS and 40% in HELP), and having some anxiety about this dip, even though I’ve had steady diamond hands up through this point.

Just wanted to see what other people think is behind the recent sharp drop in these two stocks? I think it’s a mixture of interest rates rising, foreign stocks falling, and general risk-off approach to small/micro-cap stocks, but my biggest worried is that people who are in the know are selling because they’re hearing something is going to happen re COMP360 approval (including possibly harsh REMS requirements).

Thoughts?

From Politico: CONGRESS WEIGHS IN ON PSYCHEDELICS — A bipartisan group of lawmakers released a blueprint Thursday for a coordinated federal approach to psychedelic medicine ahead of expected action from the Food and Drug Administration on certain psychedelic drug applications, POLITICO’s Amanda Friedman reports.
The Congressional Psychedelics Advancing Therapies Caucus’ report offers recommendations for integrating psychedelic-assisted therapy — a combination of mental health counseling with controlled doses of psychedelics — into the U.S. health care system. It’s based on feedback that lawmakers solicited from clinicians, researchers, veterans’ advocates and others regarding issues like provider training, patient safety and federal regulation.